Cancer Family
Malignant Skin Neoplasm
CI-CAN-00000250Explore in graph →
321 active trials14 approved drugs64 evidence items
- NCIt
- C2920
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000250Explore in graph →
Clinical trials
1,248 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07130032 | Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade(reICB) | recruiting | Phase 2 | 90 | EuroCityClinic LLCNETWORK | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04429542 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | recruiting | Phase 1 | 292 | Bicara TherapeuticsINDUSTRY |
| 3 |
| Aug 15, 2025 |
| clinicaltrials |
| NCT04620200 | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery(MATISSE) | completed | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04825834 | DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)(DELFI-L101) | completed | — | 2,992 | Delfi Diagnostics Inc.INDUSTRY | 2 | Aug 8, 2025 | clinicaltrials |
| NCT06715592 | ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study | active not recruiting | Phase 2 | 18 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 230 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT06754904 | Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node(OMIT) | recruiting | N/A | 213 | D.J. (Dirk) GrünhagenOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05879458 | Ritlecitinib in CTCL | terminated | Phase 2 | 7 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT05033678 | Implementation of Teledermoscopy and Artificial Intelligence | recruiting | — | 8,000 | Region SkaneOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07068568 | Dose-Modulated Sonidegib Therapy for Periocular Basal Cell Carcinoma(BCC-Sonidegib) | completed | — | 12 | Federico II UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06654999 | How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions. | completed | — | 115 | Skin Analytics LimitedINDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06385522 | A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System | not yet recruiting | Phase 1 | 37 | Boston Immune Technologies and TherapeuticsINDUSTRY | 0 | Jul 8, 2025 | clinicaltrials |
| NCT00832429 | Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07046663 | Long-term Assessment of Chlormethine Gel in Mycosis Fungoides(FIL_CLOR-CTCL) | not yet recruiting | — | 190 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03737721 | The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy(UNSCARRed) | terminated | Phase 2 | 8 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05538988 | BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma(BIOSELECT) | withdrawn | Phase 1 / Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07031830 | APA (Adapted Physical Activity) for Patients With Advanced Melanoma(APA-M) | recruiting | — | 50 | University Hospital, RouenOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT04305795 | An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 23 | Rakuten Medical, Inc.INDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT05188729 | Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma | completed | Phase 2 | 92 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06384053 | Skin Cancer and Hyperthermia and Radiotherapy(SAHARA) | recruiting | N/A | 100 | Kantonsspital Winterthur KSWOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT03325101 | Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma | terminated | Phase 1 / Phase 2 | 7 | Mayo ClinicOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05106192 | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05108090 | Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck | recruiting | N/A | 94 | Indiana UniversityOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04830124 | Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6(ARTISTRY-6) | terminated | Phase 2 | 173 | Mural Oncology, IncINDUSTRY | 8 | Jun 10, 2025 | clinicaltrials |
| NCT04099446 | A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer | withdrawn | — | 0 | ProgenaBiomeOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05704985 | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | active not recruiting | Phase 1 | 39 | DEKA BiosciencesINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06823479 | Towards Cure Via Only Ultra-short ICB in CSCC(MATISSE 2) | recruiting | Phase 2 | 41 | The Netherlands Cancer InstituteOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT02760498 | Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 432 | Regeneron PharmaceuticalsINDUSTRY | 8 | May 28, 2025 | clinicaltrials |
| NCT03108131 | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | completed | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06989216 | Multi-modal Quantitative Imaging of the Skin(DermaFlow) | recruiting | — | 8,000 | HJN Sverige AB/Neko HealthINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT05970497 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 240 | Krystal Biotech, Inc.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT06976073 | Non-invasive Imaging for In-vivo Quantification of Skin Composition and Structure(Spectrum1) | recruiting | — | 8,000 | HJN Sverige AB/Neko HealthINDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT02318771 | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | completed | Phase 1 | 41 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT00368784 | T Cell Repertoire Analysis of Immune Mediated Skin Diseases | completed | — | 426 | University of California, DavisOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05135052 | Rhenium-Skin Cancer Therapy (SCT) for the Treatment of Non-Melanoma Skin Cancer.(EPIC-Skin) | active not recruiting | N/A | 210 | OncoBeta TherapeuticsINDUSTRY | 5 | May 14, 2025 | clinicaltrials |
| NCT03524326 | Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | completed | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06965231 | Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial(FUMS-EDJS2024) | recruiting | Phase 2 | 58 | Fudan UniversityOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT04385732 | Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients(IMAGE) | active not recruiting | N/A | 670 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT04329221 | Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT04642287 | Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT06952400 | The Registry Study of Genetic Alterations of Melanoma in Taiwan(Melanoma) | recruiting | — | 250 | National Health Research Institutes, TaiwanOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05648604 | Mentored Community Gardening for Individuals With Skin Cancer(H4H2-AZ) | completed | N/A | 29 | University of ArizonaOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT02548468 | Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT06644079 | Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT06382844 | Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL | recruiting | — | 100 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | May 1, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Aug 19, 2025source: clinicaltrials